Intermediate of API

180272-14-4

  • Product Name：SOLIFENACIN
  • Molecular Formula：C23H26N2O2
  • Specifications：99%
  • Molecular Weight：362.46
Inquiry

Product Details;

CasNo： 180272-14-4

Molecular Formula： C23H26N2O2

High Purity SOLIFENACIN 180272-14-4 In Medicine Best Price

  • Molecular Formula:C23H26N2O2
  • Molecular Weight:362.46
  • Vapor Pressure:2.41E-10mmHg at 25°C 
  • Refractive Index:1.648 
  • Boiling Point:505.5 °C at 760 mmHg 
  • PKA:9.03±0.33(Predicted) 
  • Flash Point:259.5 °C 
  • PSA：32.78000 
  • Density:1.24 g/cm3 
  • LogP:3.74070 

SOLIFENACIN(Cas 180272-14-4) Usage

Uses

Racemic Solifenacin Succinate is a muscarinic M3 receptor antagoinst used in treatment of urinary incontinence.

IUPAC Name: 1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate  
Isomeric SMILES: C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5  
InChIKey: FBOUYBDGKBSUES-UHFFFAOYSA-N  
InChI: InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2  

180272-14-4 Relevant articles

The Effectiveness of Tamsulosin, Solifenacin, and Combinations Therapy Tamsulosin Added Solifenacin on Lower Urinary Tract Symptoms After Doubles J Stent Insertion

Ida Bagus Putra Pramana and Fikri Rizaldi and Tarmono Djojodimedjo

Indonesian Journal of Urology, 26 (2). pp. 151-159.

This study was a randomized placebo-controlled trial. There were 4 groups, group I received placebo, group II received tamsulosin 0.4 mg/day, group III received solifenacin 5 mg/day, and group IV received combination therapy of tamsulosin 0.4 mg/day added solifenacin 5 mg/day. Evaluation based on International Prostatic Symptom Score (IPSS) and Ureteral Stent Symptom Questioner (USSQ) score.

Two green chromatographic methods for the quantification of tamsulosin and solifenacin along with four of their impurities

EB Kamel

Journal of Separation Science, 2022

Two selective, sensitive, and green liquid chromatography methods were established and fully validated for quantitation of tamsulosin hydrochloride and solifenacin succinate along with four of their official and/or related impurities namely; tamsulosin sulfonic acid, tamsulosin impurity H, solifenacin impurity A and solifenacin impurity C.

180272-14-4 Process route

(S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline
180468-42-2

(S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline

(R)-quinuclidin-3-ol
25333-42-0

(R)-quinuclidin-3-ol

(1S)-3,4-dihydro-1-phenyl-2-(1H)-isoquinolinecarboxylic acid (3S)-1-azabicyclo[2.2.2]oct-3-yl ester
732228-02-3,180272-14-4

(1S)-3,4-dihydro-1-phenyl-2-(1H)-isoquinolinecarboxylic acid (3S)-1-azabicyclo[2.2.2]oct-3-yl ester

(3R)-1-azabicyclo[2.2.2]oct-3-yl (1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate
740780-79-4,180272-14-4

(3R)-1-azabicyclo[2.2.2]oct-3-yl (1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate

(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline
22990-19-8,96719-89-0,118864-75-8

(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline

solifenacin
242478-37-1,180272-14-4

solifenacin

Conditions
Conditions Yield
With potassium 2-methylbutan-2-olate; In toluene; at 90 ℃; for 3h; Product distribution / selectivity;
1.1%
3.2%
6%
(S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline
180468-42-2

(S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline

(R)-quinuclidin-3-ol
25333-42-0

(R)-quinuclidin-3-ol

(1S)-3,4-dihydro-1-phenyl-2-(1H)-isoquinolinecarboxylic acid (3S)-1-azabicyclo[2.2.2]oct-3-yl ester
732228-02-3,180272-14-4

(1S)-3,4-dihydro-1-phenyl-2-(1H)-isoquinolinecarboxylic acid (3S)-1-azabicyclo[2.2.2]oct-3-yl ester

(3R)-1-azabicyclo[2.2.2]oct-3-yl (1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate
740780-79-4,180272-14-4

(3R)-1-azabicyclo[2.2.2]oct-3-yl (1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate

(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline
22990-19-8,96719-89-0,118864-75-8

(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline

solifenacin
242478-37-1,180272-14-4

solifenacin

Conditions
Conditions Yield
With potassium 2-methylbutan-2-olate; In toluene; at 90 ℃; for 3h; Product distribution / selectivity;
1.1%
3.2%
6%

180272-14-4 Upstream products

  • 180468-42-2
    180468-42-2

    (S)-N-carboxylic acid ethyl ester-1-phenyl-1,2,3,4-tetrahydroisoquinoline

  • 25333-42-0
    25333-42-0

    (R)-quinuclidin-3-ol

  • 52250-50-7
    52250-50-7

    1-phenyl-3,4-dihydroisoquinoline

  • 3278-14-6
    3278-14-6

    N-phenethylbenzamide

180272-14-4 Downstream products

  • 180468-37-5
    180468-37-5

    Solifenacin hydrochloride

  • 1172614-17-3
    1172614-17-3

    solifenacin hydrogen adipate

  • 180272-28-0
    180272-28-0

    (1'S,3R)-3-[[(1'-phenyl-1',2',3',4'-tetrahydro-2'-isoquinolyl)carbonyl]oxy]quinuclidine 1-oxide

  • 865813-75-8
    865813-75-8

    (-)-(3R)-quinuclidin-3-yl (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate naphthalene-2-sulfonate

Relevant Products